These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25091612)

  • 1. Skin cancer: less is as good as more in refractory melanoma.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Sep; 11(9):502. PubMed ID: 25091612
    [No Abstract]   [Full Text] [Related]  

  • 2. Melanoma: immune checkpoint blockade story gets better.
    Bhatia S; Thompson JA
    Lancet; 2014 Sep; 384(9948):1078-9. PubMed ID: 25034863
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination checkpoint blockade--taking melanoma immunotherapy to the next level.
    Riley JL
    N Engl J Med; 2013 Jul; 369(2):187-9. PubMed ID: 23724866
    [No Abstract]   [Full Text] [Related]  

  • 4. From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma.
    Razzak M
    Nat Rev Clin Oncol; 2013 Jul; 10(7):365. PubMed ID: 23752732
    [No Abstract]   [Full Text] [Related]  

  • 5. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.
    Gangadhar TC; Schuchter LM
    JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
    Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
    Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
    Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca R; Gangadhar TC; Patnaik A; Zarour H; Joshua AM; Gergich K; Elassaiss-Schaap J; Algazi A; Mateus C; Boasberg P; Tumeh PC; Chmielowski B; Ebbinghaus SW; Li XN; Kang SP; Ribas A
    N Engl J Med; 2013 Jul; 369(2):134-44. PubMed ID: 23724846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin cancer. Golden age of melanoma therapy.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Jan; 12(1):1. PubMed ID: 25511188
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
    Bernard-Tessier A; Jeanville P; Champiat S; Lazarovici J; Voisin AL; Mateus C; Lambotte O; Annereau M; Michot JM
    Eur J Cancer; 2017 Aug; 81():135-137. PubMed ID: 28624693
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO; Shapera S; Butler MO; Tsao MS
    Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
    Fløe LE; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 16. Rare heart risk found with checkpoint inhibitors.
    Printz C
    Cancer; 2017 May; 123(9):1483-1484. PubMed ID: 28430361
    [No Abstract]   [Full Text] [Related]  

  • 17. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
    Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
    J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab success in untreated metastatic melanoma.
    Wilkinson E
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
    [No Abstract]   [Full Text] [Related]  

  • 20. PD-1 inhibitor becomes "breakthrough therapy".
    Cancer Discov; 2013 Jul; 3(7):OF14. PubMed ID: 23847357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.